- Front page - Faron
Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on creating innovative cancer treatments that leverage the patient’s own immune system
- Inside Information: Faron Intends to Issue Second…
The Board of Directors of Faron (the " Board ") has today resolved that the Company intends to issue the Second Tranche Bonds The Company has also today, in accordance with the Subscription Agreement, delivered a request notice concerning the Second Tranche Bonds to HCM as the initial subscriber, requesting subscription by HCM of the Second
- Faron Pharmaceuticals Oy (HEL:FARON) Company Profile Description
Company profile for Faron Pharmaceuticals Oy (HEL:FARON) with a description, list of executives, contact details and other key facts
- Faron Pharmaceuticals - Wikipedia
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer
- Faron Pharmaceuticals Ltd: Grant of Options - Yahoo Finance
TURKU, FI ACCESS Newswire December 2, 2025 Faron Pharmaceuticals Ltd (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel
- Faron Pharmaceuticals Ltd: Appointment of CFO - BioSpace
About Faron Pharmaceuticals Ltd Faron (AIM:FARN, First North:FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system
- Faron Pharmaceuticals Appoints New CFO to Drive Growth
Faron Pharmaceuticals Ltd is a global, clinical-stage biopharmaceutical company focused on developing novel immunotherapies to tackle cancers Its lead asset, bexmarilimab, is an innovative
- Faron Pharmaceuticals Oy (FARN) Share Price, News Analysis
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage
|